Entry ID,Ligand,Value,Symbol,Type,Unit,PDB ID,Title,Structure Title,Stucture Keywords,Gene Name,EC Number,Annotation Identifier,Entity ID,Entry Id (Polymer Entity Identifiers),Target Protein,Accession Code(s),Database Name,Ligand Formula,Ligand MW,Ligand ID,Ligand Name,Ligand SMILES,Entity ID
7QOX,,,,,,7QOX,Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI.,Factor XI and Plasma Kallikrein apple domain structures reveals different kininogen bound complexes,BLOOD CLOTTING,"KNG1, BDK, KNG",,"GO:0072562, GO:0062023, GO:0005788, GO:0070062, GO:0005576, GO:0005615, GO:0005886, GO:0031093, GO:0004869, GO:0004866, GO:0008201, GO:0005102, GO:0008270, GO:0061844, GO:0007596, GO:0006954, GO:0031640, GO:0030195, GO:0007162, GO:0010951, GO:0045861, GO:0043065, GO:0007204, GO:0042311, IPR000010, IPR046350, IPR002395, IPR027358, IPR018073, P01042",2,7QOX,Wildtype,P01042,UniProt,C16 H34 O8,354.436,PE4,2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL,CCOCCOCCOCCOCCOCCOCCOCCO,5
7QTM,,,,,,7QTM,Transition state analogue of small G protein in complex with relevant GAP,Transition state analogue of small G protein in complex with relevant GAP,HYDROLASE,"ARHGAP1, CDC42GAP, RHOGAP1",,"GO:0005737, GO:0005829, GO:0010008, GO:0070062, GO:0048471, GO:0045296, GO:0005096, GO:0017124, GO:0031267, GO:0016197, GO:2001136, GO:0051056, GO:0007266, GO:0007264, GO:0033572, IPR001251, IPR036865, IPR008936, IPR000198, Q07960",1,7QTM,mutant,Q07960,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,3
7QU4,,,,,,7QU4,Structural and oxidative investigation of a recombinant high-yielding fetal hemoglobin mutant.,"Recombinant Human Fetal Hemoglobin mutant - alpha subunit mutations K11E,K56E,N78D,K90E",OXYGEN TRANSPORT,"HBA1, HBA2",,"GO:0072562, GO:0005829, GO:0022627, GO:0071682, GO:0070062, GO:0005576, GO:0005615, GO:0031838, GO:0005833, GO:0016020, GO:0001664, GO:0020037, GO:0005506, GO:0043177, GO:0019825, GO:0005344, GO:0015670, GO:0098869, GO:0042744, GO:0030185, GO:0015671, GO:0042542, IPR000971, IPR009050, IPR012292, IPR002338, IPR002339, P69905",2,7QU4,mutant,P69905,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,3
7QUI,,,,,,7QUI,Structures of the Inhibitory Receptor Siglec-8 in Complex with a High-Affinity Sialoside Analogue and a Therapeutic Antibody.,Crystal structure of the N-terminal domain of Siglec-8 in complex with sulfonamide sialoside analogue,IMMUNE SYSTEM,"SIGLEC8, SAF2",,"GO:0005886, GO:0030246, GO:0033691, GO:0004888, GO:0007155, GO:0007165, IPR007110, IPR036179, IPR013783, IPR003599, IPR003598, IPR013106, Q9NYZ4",1,7QUI,mutant,Q9NYZ4,UniProt,C35 H49 N3 O23 S2,943.9,F9I,"(2~{S},4~{S},5~{R},6~{R})-5-acetamido-2-[(2~{S},3~{R},4~{S},5~{S},6~{R})-2-[(2~{R},3~{S},4~{R},5~{R},6~{R})-5-acetamido-2-(hydroxymethyl)-4,6-bis(oxidanyl)oxan-3-yl]oxy-3,5-bis(oxidanyl)-6-(sulfooxymethyl)oxan-4-yl]oxy-6-[(1~{R},2~{R})-3-(naphthalen-2-ylsulfonylamino)-1,2-bis(oxidanyl)propyl]-4-oxidanyl-oxane-2-carboxylic acid",CC(=O)NC1C(CC(OC1C(C(CNS(=O)(=O)c2ccc3ccccc3c2)O)O)(C(=O)O)OC4C(C(OC(C4O)OC5C(OC(C(C5O)NC(=O)C)O)CO)COS(=O)(=O)O)O)O,2
7RB3,,,,,,7RB3,Molecular role of NAA38 in thermostability and catalytic activity of the human NatC N-terminal acetyltransferase.,Cryo-EM structure of human binary NatC complex with a Bisubstrate inhibitor,TRANSFERASE,"NAA35, EGAP, MAK10",,"GO:0005737, GO:0005829, GO:0031417, GO:0005654, GO:0005886, GO:0017196, GO:0006474, GO:0043066, GO:0048659, IPR007244, Q5VZE5",1,7RB3,Wildtype,Q5VZE5,UniProt,C23 H38 N7 O18 P3 S,825.57,CMC,CARBOXYMETHYL COENZYME *A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSCC(=O)O)O,3
7SZA,,,,,,7SZA,Crystal Structure Analysis of human PRPK complex with a compound,Crystal Structure Analysis of human PRPK complex with a compound,TRANSFERASE,"TP53RK, C20orf64, PRPK","3.6, 2.7.11.1","GO:0005737, GO:0000408, GO:0005654, GO:0005634, GO:0005524, GO:0016787, GO:0002039, GO:0106310, GO:0004674, GO:0006468, GO:1901796, GO:0008033, GO:0070525, IPR022495, IPR011009, IPR000719, IPR008266, Q96S44",1,7SZA,Wildtype,Q96S44,UniProt,C13 H11 N3 O4,273.244,DUI,"4-amino-2-[(3R)-2,6-dioxopiperidin-3-yl]-1H-isoindole-1,3(2H)-dione",c1cc2c(c(c1)N)C(=O)N(C2=O)C3CCC(=O)NC3=O,3
7SZB,,,,,,7SZB,Crystal Structure Analysis of human PRPK complex with a compound,Crystal Structure Analysis of human PRPK complex with a compound,TRANSFERASE,"TP53RK, C20orf64, PRPK","3.6, 2.7.11.1","GO:0005737, GO:0000408, GO:0005654, GO:0005634, GO:0005524, GO:0016787, GO:0002039, GO:0106310, GO:0004674, GO:0006468, GO:1901796, GO:0008033, GO:0070525, IPR022495, IPR011009, IPR000719, IPR008266, Q96S44",1,7SZB,Wildtype,Q96S44,UniProt,C13 H11 N3 O4,273.244,DQ4,"5-amino-2-[(3R)-2,6-dioxopiperidin-3-yl]-1H-isoindole-1,3(2H)-dione",c1cc2c(cc1N)C(=O)N(C2=O)C3CCC(=O)NC3=O,3
7TAI,,,,,,7TAI,Structure of STEAP2 in complex with ligands,Structure of STEAP2 in complex with ligands,OXIDOREDUCTASE,"STEAP2, PCANAP1, STAMP1, UNQ6507/PRO23203",1.16.1,"GO:0005829, GO:0005769, GO:0005768, GO:0010008, GO:0000139, GO:0005886, GO:0030140, GO:0008823, GO:0052851, GO:0046872, GO:0015677, GO:0098705, GO:0006897, GO:0006893, GO:0098711, GO:0045055, GO:0009725, IPR013130, IPR036291, IPR028939, Q8NFT2, Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Transmembrane ferric reductase, Generic PDBTM",1,7TAI,Wildtype,Q8NFT2,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,3
7TAI,,,,,,7TAI,Structure of STEAP2 in complex with ligands,Structure of STEAP2 in complex with ligands,OXIDOREDUCTASE,"STEAP2, PCANAP1, STAMP1, UNQ6507/PRO23203",1.16.1,"GO:0005829, GO:0005769, GO:0005768, GO:0010008, GO:0000139, GO:0005886, GO:0030140, GO:0008823, GO:0052851, GO:0046872, GO:0015677, GO:0098705, GO:0006897, GO:0006893, GO:0098711, GO:0045055, GO:0009725, IPR013130, IPR036291, IPR028939, Q8NFT2, Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Transmembrane ferric reductase, Generic PDBTM",1,7TAI,Wildtype,Q8NFT2,UniProt,C21 H28 N7 O17 P3,743.405,NAP,NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)OP(=O)(O)O)O)O)O)C(=O)N,4
7TAI,,,,,,7TAI,Structure of STEAP2 in complex with ligands,Structure of STEAP2 in complex with ligands,OXIDOREDUCTASE,"STEAP2, PCANAP1, STAMP1, UNQ6507/PRO23203",1.16.1,"GO:0005829, GO:0005769, GO:0005768, GO:0010008, GO:0000139, GO:0005886, GO:0030140, GO:0008823, GO:0052851, GO:0046872, GO:0015677, GO:0098705, GO:0006897, GO:0006893, GO:0098711, GO:0045055, GO:0009725, IPR013130, IPR036291, IPR028939, Q8NFT2, Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Transmembrane ferric reductase, Generic PDBTM",1,7TAI,Wildtype,Q8NFT2,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,2
7TKX,,,,,,7TKX,Crystal structure of R14A human Galectin-7 mutant in presence of 4-O-beta-D-Galactopyranosyl-D-glucose,Crystal structure of R14A human Galectin-7 mutant in presence of 4-O-beta-D-Galactopyranosyl-D-glucose,SUGAR BINDING PROTEIN,"LGALS7, PIG1, LGALS7B",,"GO:0005829, GO:0070062, GO:0005615, GO:0005634, GO:0030246, GO:0016936, GO:0006915, GO:0007157, GO:2000562, GO:0032689, GO:0010628, IPR013320, IPR044156, IPR030640, IPR001079, P47929",1,7TKX,mutant,P47929,UniProt,C12 H22 O11,342.296,LBL,"(2~{R},3~{R},4~{R},5~{R})-4-[(2~{S},3~{R},4~{S},5~{R},6~{R})-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-2,3,5,
6-tetrakis(oxidanyl)hexanal",C(C1C(C(C(C(O1)OC(C(CO)O)C(C(C=O)O)O)O)O)O)O,2
7TMC,,,,,,7TMC,TMEM106B filament from human brain,TMEM106B singlet filament extracted from MSTD neurodegenerative human brain,NEUROPEPTIDE,TMEM106B,,"GO:0005768, GO:0031902, GO:0005765, GO:0005764, GO:0051117, GO:0048813, GO:0007042, GO:1905146, GO:0007041, GO:0032418, GO:0007040, GO:0070050, GO:1900006, GO:0051345, GO:1905671, IPR009790, Q9NUM4",1,7TMC,mutant,Q9NUM4,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,2
7UCD,,,,,,7UCD,Chemically targeting the redox switch in AP1 transcription factor Delta FOSB.,Transcription factor FosB/JunD bZIP domain covalently modified with the cysteine-targeting alpha-haloketone compound Z2159931480,DNA BINDING PROTEIN,"FOSB, G0S3",,"GO:0000785, GO:0043231, GO:0005654, GO:0005634, GO:0003677, GO:0001228, GO:0000981, GO:0000978, GO:1990837, GO:0071277, GO:0032870, GO:0007565, GO:0000122, GO:0006357, GO:0051591, GO:0051412, GO:0009612, GO:0043278, GO:0032570, GO:0009410, GO:0006366, IPR000837, IPR004827, IPR046347, IPR029813, P53539",1,7UCD,Wildtype,P53539,UniProt,C11 H10 O4,206.195,MV0,7-acetyl-4-methoxy-1-benzofuran-3(2H)-one,CC(=O)c1ccc(c2c1OCC2=O)OC,3
7UD6,,,,,,7UD6,Designer installation of a substrate recruitment domain to tailor enzyme specificity.,Designed Enzyme SH3-588 (Catechol O-methyltransferase catalytic domain and Src homology 3 binding domain fusion),TRANSFERASE,FYN,2.1.1.6,"GO:0030424, GO:0044297, GO:0005829, GO:0030425, GO:0043197, GO:0016020, GO:0045211, GO:0016206, GO:0102084, GO:0000287, GO:0008171, GO:0102938, GO:0042424, GO:0016036, GO:0032502, GO:0042420, GO:0042417, GO:0008210, GO:0007565, GO:0007612, GO:0032259, GO:0048609, GO:0045963, GO:0035814, GO:0048662, GO:0042135, GO:0050668, GO:0051930, GO:0043627, GO:0032496, GO:0014070, GO:0048265, GO:0009410, GO:0046498, GO:0046500, GO:0007614, IPR017128, IPR029063, IPR002935, GO:0005886, IPR035750, IPR000980, IPR036860, IPR036028, IPR001452, P22734",1,7UD6,mutant,E5RFS5,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,2
7WMM,,,,,,7WMM,alpha-synuclein fibril-F0502B complex,alpha-synuclein fibril-F0502B complex,PROTEIN FIBRIL,"SNCA, NACP, PARK1",,"GO:0015629, GO:0070161, GO:0030424, GO:0043679, GO:0005938, GO:0005737, GO:0005829, GO:0005576, GO:0005615, GO:0030426, GO:0016234, GO:0005764, GO:0016020, GO:0005739, GO:0043025, GO:0005634, GO:0048471, GO:0005886, GO:0098794, GO:0032991, GO:0099512, GO:0030672, GO:0003779, GO:0043014, GO:0005509, GO:0005507, GO:1903136, GO:0043027, GO:0070840, GO:0008198, GO:0042393, GO:0030544, GO:0042802, GO:0019894, GO:0000287, GO:0016491, GO:0005543, GO:0051219, GO:0004860, GO:0000149, GO:0048156, GO:0000976, GO:0008270, GO:0006919, GO:0008344, GO:0071280, GO:0071872, GO:0034599, GO:0007268, GO:0042416, GO:0051583, GO:0060079, GO:0006631, GO:0060291, GO:0001774, GO:0042775, GO:0007006, GO:0043066, GO:1904715, GO:0043154, GO:0051585, GO:0045920, GO:0035067, GO:0031115, GO:1902957, GO:0032769, GO:0043524, GO:1901215, GO:0051622, GO:0010642, GO:0006469, GO:0051612, GO:0070495, GO:0000122, GO:0032410, GO:0051402, GO:0006638, GO:0006644, GO:0043065, GO:0045807, GO:0045921, GO:1903284, GO:1903285, GO:0050729, GO:0060732, GO:1901216, GO:0001956, GO:0033138, GO:0071902, GO:0001921, GO:0051281, GO:0035543, GO:0031648, GO:0051262, GO:0031623, GO:0050812, GO:0014059, GO:0014048, GO:0040012, GO:0048169, GO:0043030, GO:1901214, GO:0051621, GO:0010517, GO:1905606, GO:1903426, GO:1903421, GO:0022898, GO:0034341, GO:0070555, GO:0010040, GO:0032496, GO:0032026, GO:0009410, GO:0035493, GO:0097435, GO:0050808, GO:0048488, GO:0016079, GO:0016082, GO:0048489, IPR001058, IPR002460, P37840",1,7WMM,Wildtype,P37840,UniProt,C21 H22 Br F N2 O2 S,465.379,1KI,"2-bromanyl-4-[(~{E})-2-[6-[2-(2-fluoranylethoxy)ethyl-methyl-amino]-5-methyl-1,3-benzothiazol-2-yl]ethenyl]phenol",Cc1cc2c(cc1N(C)CCOCCF)sc(n2)C=Cc3ccc(c(c3)Br)O,2
7WR3,,,,,,7WR3,Structural mechanisms of calmodulin activation of Shigella effector OspC3 to ADP-riboxanate caspase-4/11 and block pyroptosis.,Crystal structure of MBP-fused OspC3 in complex with calmodulin,TRANSFERASE,"CALM1, CALM, CAM, CAM1",,"GO:0034704, GO:1902494, GO:0005813, GO:0005737, GO:0005829, GO:0005576, GO:0043209, GO:0005654, GO:0005634, GO:0005886, GO:0032991, GO:0030017, GO:0097225, GO:0005876, GO:0000922, GO:0031982, GO:0008076, GO:0010856, GO:0008179, GO:0019855, GO:0005509, GO:0048306, GO:0097718, GO:0030234, GO:0019904, GO:0019901, GO:0072542, GO:0043539, GO:0031432, GO:0044325, GO:0016240, GO:0005513, GO:0007186, GO:0000086, GO:1990456, GO:1905913, GO:1901842, GO:0010801, GO:0060315, GO:0140056, GO:0051343, GO:0043388, GO:0010800, GO:0032516, GO:0031954, GO:0035307, GO:0071902, GO:0060316, GO:0050848, GO:0098901, GO:0055117, GO:0010881, GO:1901844, GO:0032465, GO:0002027, GO:0010880, GO:0060314, GO:0051592, GO:0021762, IPR011992, IPR018247, IPR002048, P0DP23",2,7WR3,mutant,P0DP23,UniProt,C6 H6 N2 O,122.125,NCA,NICOTINAMIDE,c1cc(cnc1)C(=O)N,5
7WR5,,,,,,7WR5,Structural mechanisms of calmodulin activation of Shigella effector OspC3 to ADP-riboxanate caspase-4/11 and block pyroptosis.,Crystal structure of OspC3-calmodulin-caspase-4 complex binding with 2'-aF-NAD+,TRANSFERASE,"CASP4, ICH2",3.4.22.57,"GO:0097169, GO:0005737, GO:0005829, GO:0005783, GO:0005789, GO:0005576, GO:0072557, GO:0005739, GO:0072559, GO:0005886, GO:0032991, GO:0050700, GO:0004197, GO:0097199, GO:0006915, GO:1904646, GO:0050830, GO:0006954, GO:0045087, GO:0097193, GO:0070059, GO:0050729, GO:2000494, GO:1903265, GO:0016540, GO:0006508, GO:0070269, GO:0042981, GO:0050727, IPR001315, IPR029030, IPR033139, IPR016129, IPR011029, IPR002398, IPR002138, IPR001309, IPR015917, P49662",3,7WR5,mutant,P49662,UniProt,C21 H27 F N7 O13 P2,666.424,5ZV,"[[(2~{R},3~{R},4~{S},5~{R})-5-(3-aminocarbonylpyridin-1-yl)-4-fluoranyl-3-oxidanyl-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate",c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)[N]5=CC=CC(=C5)C(=O)N)F)O)O)O)N,4
7WR6,,,,,,7WR6,Structural mechanisms of calmodulin activation of Shigella effector OspC3 to ADP-riboxanate caspase-4/11 and block pyroptosis.,Crystal structure of ADP-riboxanated caspase-4 in complex with Af1521,HYDROLASE,AF_1521,3.2.2,"GO:0140293, GO:0140291, IPR002589, IPR043472",2,7WR6,mutant,O28751,UniProt,C21 H32 N8 O14 P2,682.472,5ZY,"[[(3~{a}~{S},5~{R},6~{R},6~{a}~{R})-2-azanylidene-3-[(4~{R})-4-azanyl-5-oxidanylidene-pentyl]-6-oxidanyl-3~{a},5,6,6~{a}-tetrahydrofuro[2,3-d][1,3]oxazol-5-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate",c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OCC4C(C5C(O4)N(C(=N)O5)CCCC(C=O)N)O)O)O)N,3
7WVD,,,,,,7WVD,Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes.,Crystal structure of H14 complexed with SIA28,VIRUS,HA,,"GO:0016324, GO:0020002, GO:0019031, GO:0055036, GO:0046789, GO:0075512, GO:0039654, GO:0019064, GO:0046761, GO:0019062, IPR008980, IPR013828, IPR000149, IPR001364",1,7WVD,Wildtype,L7YN49,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7WVG,,,,,,7WVG,Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes.,Crystal structure of H18 complexed with SIA28,VIRUS,HA,,"GO:0016324, GO:0020002, GO:0019031, GO:0055036, GO:0046789, GO:0075512, GO:0039654, GO:0019064, GO:0046761, GO:0019062, IPR008980, IPR013828, IPR000149, IPR001364",1,7WVG,Wildtype,A0A1W5II89,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,8
7XBF,,,,,,7XBF,Host range and structural analysis of bat-origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs.,The complex structure of RshSTT182/200 RBD-insert2 bound to human ACE2,VIRAL PROTEIN,"ACE2, UNQ868/PRO1885","3.4.17.23, 3.4.17","GO:0016324, GO:0031526, GO:0009986, GO:0005929, GO:0030666, GO:0005788, GO:0070062, GO:0005576, GO:0005615, GO:0016020, GO:0045121, GO:0005886, GO:0004180, GO:0004175, GO:0042802, GO:0004181, GO:0008237, GO:0008241, GO:0001618, GO:0008270, GO:0002003, GO:0003051, GO:0097746, GO:0060135, GO:0061025, GO:0070373, GO:2000272, GO:0048662, GO:0051957, GO:0060452, GO:1903598, GO:1905737, GO:2000379, GO:0019065, GO:0046813, GO:1903779, GO:0042127, GO:0001817, GO:0050727, GO:0003081, GO:0022898, GO:0019229, GO:0015827, GO:0046718, GO:0019058, IPR031588, IPR001548, Q9BYF1",1,7XBF,Wildtype,Q9BYF1,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,3
7XBG,,,,,,7XBG,Host range and structural analysis of bat-origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs.,The crystal structure of RshSTT182/200 RBD-insert2-T346R-Y496G mutant in complex with human ACE2,VIRAL PROTEIN,"ACE2, UNQ868/PRO1885","3.4.17.23, 3.4.17","GO:0016324, GO:0031526, GO:0009986, GO:0005929, GO:0030666, GO:0005788, GO:0070062, GO:0005576, GO:0005615, GO:0016020, GO:0045121, GO:0005886, GO:0004180, GO:0004175, GO:0042802, GO:0004181, GO:0008237, GO:0008241, GO:0001618, GO:0008270, GO:0002003, GO:0003051, GO:0097746, GO:0060135, GO:0061025, GO:0070373, GO:2000272, GO:0048662, GO:0051957, GO:0060452, GO:1903598, GO:1905737, GO:2000379, GO:0019065, GO:0046813, GO:1903779, GO:0042127, GO:0001817, GO:0050727, GO:0003081, GO:0022898, GO:0019229, GO:0015827, GO:0046718, GO:0019058, IPR031588, IPR001548, Q9BYF1",1,7XBG,Wildtype,Q9BYF1,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7XBH,,,,,,7XBH,Host range and structural analysis of bat-origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs.,The complex structure of RshSTT182/200 RBD bound to human ACE2,VIRAL PROTEIN,"ACE2, UNQ868/PRO1885","3.4.17.23, 3.4.17","GO:0016324, GO:0031526, GO:0009986, GO:0005929, GO:0030666, GO:0005788, GO:0070062, GO:0005576, GO:0005615, GO:0016020, GO:0045121, GO:0005886, GO:0004180, GO:0004175, GO:0042802, GO:0004181, GO:0008237, GO:0008241, GO:0001618, GO:0008270, GO:0002003, GO:0003051, GO:0097746, GO:0060135, GO:0061025, GO:0070373, GO:2000272, GO:0048662, GO:0051957, GO:0060452, GO:1903598, GO:1905737, GO:2000379, GO:0019065, GO:0046813, GO:1903779, GO:0042127, GO:0001817, GO:0050727, GO:0003081, GO:0022898, GO:0019229, GO:0015827, GO:0046718, GO:0019058, IPR031588, IPR001548, Q9BYF1",1,7XBH,Wildtype,Q9BYF1,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,3
7XBK,,,,,,7XBK,Comprehensive structural characterization of the human AAA+ disaggregase CLPB in the apo- and substrate-bound states reveals a unique mode of action driven by oligomerization.,Structure and mechanism of a mitochondrial AAA+ disaggregase CLPB,CHAPERONE,"CLPB, HSP78, SKD3",3.6.1,"GO:0005737, GO:0005758, GO:0005739, GO:0005524, GO:0016887, GO:0140374, GO:0034605, GO:0039529, IPR003593, IPR002110, IPR036770, IPR003959, IPR019489, IPR001270, IPR027417, Q9H078",1,7XBK,mutant,Q9H078,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
7XQG,,,,,,7XQG,Conformational changes in the human Cx43/GJA1 gap junction channel visualized using cryo-EM.,Hemichannel-focused structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE nanodiscs (GCN conformation),MEMBRANE PROTEIN,"GJA1, GJAL",,"GO:0016324, GO:0030054, GO:0044291, GO:0005922, GO:0005737, GO:0005789, GO:0005925, GO:0005921, GO:0005794, GO:0000139, GO:0030660, GO:0014704, GO:0043231, GO:0045121, GO:0005739, GO:0005654, GO:0005634, GO:0005886, GO:0070160, GO:0043014, GO:0008013, GO:0015562, GO:0005243, GO:0086075, GO:1903763, GO:0055077, GO:0034634, GO:0015075, GO:0015631, GO:0086014, GO:0060348, GO:0046849, GO:0003161, GO:0010644, GO:0086064, GO:0007267, GO:1904646, GO:0000132, GO:0140115, GO:0016264, GO:0014047, GO:0034220, GO:0035633, GO:0099111, GO:0030308, GO:0032277, GO:1901164, GO:0120162, GO:0010628, GO:0043123, GO:1905772, GO:1905332, GO:2000648, GO:1904707, GO:0008104, GO:0007165, GO:0007283, GO:0042908, IPR035091, IPR000500, IPR002261, IPR013124, IPR034634, IPR019570, IPR017990, IPR013092, IPR038359, P17302, Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin, Generic PDBTM",1,7XQG,Wildtype,P17302,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,3
7Y5N,,,,,,7Y5N,Structural insights into the covalent regulation of PAPP-A activity by proMBP and STC3.,Structure of 1:2 PAPP-A.ProMBP complex(half map),METAL BINDING PROTEIN/HYDROLASE,PAPPA,3.4.24.79,"GO:0005576, GO:0005615, GO:0004222, GO:0008237, GO:0008270, GO:0007166, GO:0007565, GO:0030163, GO:0006508, GO:0071548, GO:0032354, IPR013320, IPR006558, IPR024079, IPR011936, IPR000800, IPR030433, IPR043543, IPR008754, IPR035976, IPR000436, Q13219",2,7Y5N,Wildtype,Q13219,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7Y76,,,,,,7Y76,Structures of ACE2-SIT1 recognized by Omicron variants of SARS-CoV-2.,SIT1-ACE2-BA.5 RBD,VIRAL PROTEIN/HYDROLASE,"SLC6A20, SIT1, XT3, XTRP3",,"GO:0016324, GO:0005886, GO:0015171, GO:0015199, GO:0015188, GO:0015193, GO:0015175, GO:0005298, GO:0015370, GO:0089718, GO:0006865, GO:0015838, GO:1903804, GO:0015816, GO:1903806, GO:1904271, GO:1905647, GO:0015824, GO:0035725, GO:0150104, IPR000175, IPR002438, IPR037272, Q9NP91, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter",1,7Y76,mutant,Q9NP91,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7Y76,,,,,,7Y76,Structures of ACE2-SIT1 recognized by Omicron variants of SARS-CoV-3.,SIT1-ACE2-BA.6 RBD,VIRAL PROTEIN/HYDROLASE,"ACE2, UNQ868/PRO1885","3.4.17.23, 3.4.17","GO:0016324, GO:0031526, GO:0009986, GO:0005929, GO:0030666, GO:0005788, GO:0070062, GO:0005576, GO:0005615, GO:0016020, GO:0045121, GO:0005886, GO:0004180, GO:0004175, GO:0042802, GO:0004181, GO:0008237, GO:0008241, GO:0001618, GO:0008270, GO:0002003, GO:0003051, GO:0097746, GO:0060135, GO:0061025, GO:0070373, GO:2000272, GO:0048662, GO:0051957, GO:0060452, GO:1903598, GO:1905737, GO:2000379, GO:0019065, GO:0046813, GO:1903779, GO:0042127, GO:0001817, GO:0050727, GO:0003081, GO:0022898, GO:0019229, GO:0015827, GO:0046718, GO:0019058, IPR031588, IPR001548, Q9BYF1, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Neurotransmitter: sodium symporter",2,7Y76,mutant,Q9BYF1,UniProt,C39 H77 O8 P,704.998,3PH,"1,2-DIACYL-GLYCEROL-3-SN-PHOSPHATE",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCCCCCCCCCCCC,6
7Z87,,,,,,7Z87,Human DNA-dependent protein kinase activation mechanism.,DNA-PK in the active state,DNA BINDING PROTEIN,"PRKDC, HYRC, HYRC1",2.7.11.1,"GO:0000781, GO:0005829, GO:0070418, GO:0005958, GO:0016020, GO:0070419, GO:0005730, GO:0005654, GO:0005634, GO:0032991, GO:0032993, GO:0032040, GO:0005667, GO:0005524, GO:0004677, GO:0003690, GO:0019899, GO:0019904, GO:0004672, GO:0106310, GO:0004674, GO:0003723, GO:0061629, GO:0034511, GO:0002218, GO:0002326, GO:0007420, GO:0006974, GO:0032869, GO:0006302, GO:0097681, GO:0006303, GO:0035234, GO:0007507, GO:0002327, GO:0033152, GO:0045087, GO:0008630, GO:0000460, GO:0031571, GO:0043066, GO:0001933, GO:0018105, GO:0018107, GO:0043065, GO:2001034, GO:0045648, GO:0045621, GO:1905221, GO:0045944, GO:0045727, GO:0002328, GO:0031648, GO:0036211, GO:0006468, GO:0042752, GO:0050678, GO:1902036, GO:0048660, GO:0010332, GO:0048511, GO:0034462, GO:0001756, GO:0033077, GO:0002360, GO:0033153, GO:0016233, GO:0000723, IPR011989, IPR016024, IPR037706, IPR012582, IPR045581, IPR003152, IPR011009, IPR000403, IPR036940, IPR018936, IPR003151, IPR014009, P78527",1,7Z87,Wildtype,P78527,UniProt,C24 H21 Cl F N5 O3,481.907,1IX,(~{S})-[2-chloranyl-4-fluoranyl-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol,COc1ccc(nn1)C(c2cc(c(cc2Cl)F)c3c4ccc(cc4ncn3)N5CCOCC5)O,6
7Z88,,,,,,7Z88,Human DNA-dependent protein kinase activation mechanism.,DNA-PK in the intermediate state,DNA BINDING PROTEIN,"PRKDC, HYRC, HYRC1",2.7.11.1,"GO:0000781, GO:0005829, GO:0070418, GO:0005958, GO:0016020, GO:0070419, GO:0005730, GO:0005654, GO:0005634, GO:0032991, GO:0032993, GO:0032040, GO:0005667, GO:0005524, GO:0004677, GO:0003690, GO:0019899, GO:0019904, GO:0004672, GO:0106310, GO:0004674, GO:0003723, GO:0061629, GO:0034511, GO:0002218, GO:0002326, GO:0007420, GO:0006974, GO:0032869, GO:0006302, GO:0097681, GO:0006303, GO:0035234, GO:0007507, GO:0002327, GO:0033152, GO:0045087, GO:0008630, GO:0000460, GO:0031571, GO:0043066, GO:0001933, GO:0018105, GO:0018107, GO:0043065, GO:2001034, GO:0045648, GO:0045621, GO:1905221, GO:0045944, GO:0045727, GO:0002328, GO:0031648, GO:0036211, GO:0006468, GO:0042752, GO:0050678, GO:1902036, GO:0048660, GO:0010332, GO:0048511, GO:0034462, GO:0001756, GO:0033077, GO:0002360, GO:0033153, GO:0016233, GO:0000723, IPR011989, IPR016024, IPR037706, IPR012582, IPR045581, IPR003152, IPR011009, IPR000403, IPR036940, IPR018936, IPR003151, IPR014009, P78527",1,7Z88,Wildtype,P78527,UniProt,C24 H21 Cl F N5 O3,481.907,1IX,(~{S})-[2-chloranyl-4-fluoranyl-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol,COc1ccc(nn1)C(c2cc(c(cc2Cl)F)c3c4ccc(cc4ncn3)N5CCOCC5)O,6
7ZTC,,,,,,7ZTC,Structural basis underlying specific biochemical activities of non-muscle tropomyosin isoforms.,Non-muscle F-actin decorated with non-muscle tropomyosin 1.6,CYTOSOLIC PROTEIN,,,"IPR004000, IPR020902, IPR004001, IPR043129",1,7ZTC,Wildtype,A0A6I9HGD1,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
7ZTD,,,,,,7ZTD,Structural basis underlying specific biochemical activities of non-muscle tropomyosin isoforms.,Non-muscle F-actin decorated with non-muscle tropomyosin 3.2,CYTOSOLIC PROTEIN,,,"IPR004000, IPR020902, IPR004001, IPR043129",1,7ZTD,Wildtype,A0A6I9HGD1,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8BYN,,,,,,8BYN,Cryo-EM structures of chronic traumatic encephalopathy tau filaments with PET ligand flortaucipir,Chronic traumatic encephalopathy tau filaments with PET ligand flortaucipir,PROTEIN FIBRIL,"MAPT, MAPTL, MTBT1, TAU",,"GO:0030673, GO:0030424, GO:1904115, GO:0044297, GO:0005737, GO:0036464, GO:0005829, GO:0030425, GO:0043197, GO:0005576, GO:0097386, GO:0030426, GO:0044304, GO:0045121, GO:0005874, GO:0015630, GO:0005739, GO:0097418, GO:0043005, GO:0043025, GO:0034399, GO:0016607, GO:0005634, GO:0005886, GO:0036477, GO:0045298, GO:0003779, GO:0034185, GO:0051087, GO:0003677, GO:0003690, GO:0034452, GO:0019899, GO:0099077, GO:0051879, GO:0042802, GO:0071813, GO:0008017, GO:0099609, GO:0003680, GO:0035091, GO:1902936, GO:0019901, GO:0051721, GO:0030674, GO:0003723, GO:0043565, GO:0017124, GO:0003697, GO:0006919, GO:1990000, GO:0048143, GO:0061564, GO:0098930, GO:0019896, GO:0007267, GO:1990416, GO:0034605, GO:1990090, GO:0034614, GO:0021954, GO:0031122, GO:0048699, GO:0006475, GO:0048312, GO:0007611, GO:0007613, GO:0001774, GO:0000226, GO:0046785, GO:1903748, GO:0010629, GO:0033673, GO:0090258, GO:0010917, GO:1904428, GO:1902988, GO:0031175, GO:0072386, GO:0045773, GO:1905689, GO:0031116, GO:1901216, GO:1903829, GO:1902474, GO:0032930, GO:0051260, GO:0051258, GO:0010506, GO:0050848, GO:1900034, GO:0033044, GO:1900452, GO:0070507, GO:0031113, GO:0031110, GO:0090140, GO:0048167, GO:0010288, GO:0016072, GO:0034063, GO:0097435, GO:0007416, GO:0050808, IPR001084, IPR002955, P10636",1,8BYN,Wildtype,P10636,UniProt,C16 H10 F N3,263.269,S9C,"7-(6-fluoranylpyridin-3-yl)-5~{H}-pyrido[4,3-b]indole",c1cc2c(cc1c3ccc(nc3)F)[nH]c4c2cncc4,2
8CZK,,,,,,8CZK,The mechanism of thia-Michael addition catalyzed by LanC enzymes.,Human LanCL1 bound to GSH and Dhb-Erk peptide,SIGNALING PROTEIN,"LANCL1, GPR69A",2.5.1.18,"GO:0005737, GO:0005886, GO:0004930, GO:0043295, GO:0004364, GO:0050750, GO:0017124, GO:0008270, GO:0005975, GO:0007186, GO:0043523, IPR012341, IPR007822, IPR020464, O43813",2,8CZK,Wildtype,O43813,UniProt,C10 H17 N3 O6 S,307.323,GSH,GLUTATHIONE,C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N,4
8CZL,,,,,,8CZL,The mechanism of thia-Michael addition catalyzed by LanC enzymes.,Human LanCL1 bound to methyl glutathione (MeGSH),SIGNALING PROTEIN,"LANCL1, GPR69A",2.5.1.18,"GO:0005737, GO:0005886, GO:0004930, GO:0043295, GO:0004364, GO:0050750, GO:0017124, GO:0008270, GO:0005975, GO:0007186, GO:0043523, IPR012341, IPR007822, IPR020464, O43813",1,8CZL,Wildtype,O43813,UniProt,C11 H19 N3 O6 S,321.35,GSM,L-GAMMA-GLUTAMYL-S-METHYLCYSTEINYLGLYCINE,CSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N,3
8D0V,,,,,,8D0V,The mechanism of thia-Michael addition catalyzed by LanC enzymes.,Human LanCL1 C264A mutant bound to GSH,SIGNALING PROTEIN,"LANCL1, GPR69A",2.5.1.18,"GO:0005737, GO:0005886, GO:0004930, GO:0043295, GO:0004364, GO:0050750, GO:0017124, GO:0008270, GO:0005975, GO:0007186, GO:0043523, IPR012341, IPR007822, IPR020464, O43813",1,8D0V,mutant,O43813,UniProt,C10 H17 N3 O6 S,307.323,GSH,GLUTATHIONE,C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N,3
8D19,,,,,,8D19,The mechanism of thia-Michael addition catalyzed by LanC enzymes.,Human LanCL1 bound to GSH,SIGNALING PROTEIN,"LANCL1, GPR69A",2.5.1.18,"GO:0005737, GO:0005886, GO:0004930, GO:0043295, GO:0004364, GO:0050750, GO:0017124, GO:0008270, GO:0005975, GO:0007186, GO:0043523, IPR012341, IPR007822, IPR020464, O43813",1,8D19,Wildtype,O43813,UniProt,C10 H17 N3 O6 S,307.323,GSH,GLUTATHIONE,C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N,3
8D59,,,,,,8D59,Structures and mechanisms of tRNA methylation by METTL1-WDR4.,Crystal structure of human METTL1 in complex with SAM,TRANSFERASE,"METTL1, C12orf1","2.1.1.33, 2.1.1","GO:0005829, GO:0005730, GO:0005654, GO:0005634, GO:0043527, GO:0008176, GO:0000049, GO:0036265, GO:0030488, GO:0006400, IPR029063, IPR025763, IPR003358, Q9UBP6",1,8D59,Wildtype,Q9UBP6,UniProt,C15 H22 N6 O5 S,398.437,SAM,S-ADENOSYLMETHIONINE,C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)n2cnc3c2ncnc3N)O)O,2
8D5B,,,,,,8D5B,Structures and mechanisms of tRNA methylation by METTL1-WDR4.,Crystal structure of human METTL1 in complex with SAH,TRANSFERASE,"METTL1, C12orf1","2.1.1.33, 2.1.1","GO:0005829, GO:0005730, GO:0005654, GO:0005634, GO:0043527, GO:0008176, GO:0000049, GO:0036265, GO:0030488, GO:0006400, IPR029063, IPR025763, IPR003358, Q9UBP6",1,8D5B,Wildtype,Q9UBP6,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,2
8D9L,,,,,,8D9L,Structures and mechanisms of tRNA methylation by METTL1-WDR4.,CryoEM structure of human METTL1-WDR4 in complex with Lys-tRNA and SAM,TRANSFERASE/RNA,WDR4,,"GO:0005694, GO:0005829, GO:0005654, GO:0005634, GO:0043527, GO:0006974, GO:0106004, GO:0006400, IPR028884, IPR015943, IPR001680, IPR036322, P57081",1,8D9L,mutant,P57081,UniProt,C15 H22 N6 O5 S,398.437,SAM,S-ADENOSYLMETHIONINE,C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)n2cnc3c2ncnc3N)O)O,4
8DKB,,,,,,8DKB,Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4.,Crystal Structure of human YEATS4 in complex with Pfizer small molecule compound 3b,PROTEIN BINDING,"YEATS4, GAS41",,"GO:0035267, GO:0016363, GO:0031965, GO:0005654, GO:0000786, GO:0005634, GO:0042393, GO:0070577, GO:0140030, GO:0005200, GO:0006338, GO:0016573, GO:0043968, GO:0043967, GO:0000278, GO:1905168, GO:0045893, GO:0042981, GO:0051726, GO:2000779, GO:0040008, GO:0006357, GO:0006355, IPR038704, IPR005033, O95619",1,8DKB,Wildtype,O95619,UniProt,C24 H36 N4 O2,412.568,SJI,"N-ethyl-1-{(3S,4S)-1-[(1-hydroxycyclohexyl)methyl]-3-methylpiperidin-4-yl}-2-methyl-1H-benzimidazole-5-carboxamide",CCNC(=O)c1ccc2c(c1)nc(n2C3CCN(CC3C)CC4(CCCCC4)O)C,2
8DOV,,,,,,8DOV,The Shr receptor from Streptococcus pyogenes uses a cap and release mechanism to acquire heme-iron from human hemoglobin.,Crystal structure of the Shr Hemoglobin Interacting Domain 2 (HID2) in complex with Hemoglobin,TRANSPORT PROTEIN,"HBA1, HBA2",,"GO:0072562, GO:0005829, GO:0022627, GO:0071682, GO:0070062, GO:0005576, GO:0005615, GO:0031838, GO:0005833, GO:0016020, GO:0001664, GO:0020037, GO:0005506, GO:0043177, GO:0019825, GO:0005344, GO:0015670, GO:0098869, GO:0042744, GO:0030185, GO:0015671, GO:0042542, IPR000971, IPR009050, IPR012292, IPR002338, IPR002339, P69905",1,8DOV,Wildtype,P69905,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,4
8E9F,,,,,,8E9F,Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.,"WD repeat-containing protein 5 complexed with 4-(7-((1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-6-ethyl-N-methylquinoline-8-carboxamide (compound 10)",TRANSCRIPTION,"WDR5, BIG3",,"GO:0140672, GO:0000123, GO:0035097, GO:0072686, GO:0071339, GO:0044665, GO:0044666, GO:0044545, GO:0005654, GO:0005634, GO:0048188, GO:0042393, GO:0035064, GO:0006325, GO:0006094, GO:0043966, GO:0044154, GO:0051568, GO:0043984, GO:0043981, GO:0043982, GO:0051572, GO:0031175, GO:0045722, GO:0051571, GO:0045893, GO:0051726, GO:0051302, GO:1900095, GO:0045995, GO:0031063, GO:0006357, GO:0006355, GO:0090043, GO:0001501, IPR020472, IPR015943, IPR001680, IPR019775, IPR036322, P61964",1,8E9F,Wildtype,P61964,UniProt,C31 H28 F3 N7 O2,587.595,UY9,"6-ethyl-4-[(5P)-7-[(1H-imidazol-1-yl)methyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl]-N-methylquinoline-8-carboxamide",CCc1cc2c(ccnc2c(c1)C(=O)NC)N3CCc4c(cc(cc4C3=O)Cn5ccnc5)c6cn(nc6C(F)(F)F)C,3
8EFE,,,,,,8EFE,Conformational changes linked to ADP release from human cardiac myosin bound to actin-tropomyosin.,Human beta-cardiac myosin II bound to ADP-MG2+ and the associated essential light chain,CONTRACTILE PROTEIN,"Myl1, Mylf",,"GO:0043292, GO:0030016, GO:0016460, GO:0005509, GO:0008307, GO:0060048, GO:0006936, IPR011992, IPR002048, P05977",2,8EFE,Wildtype,P05977,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,4
8EFH,,,,,,8EFH,Conformational changes linked to ADP release from human cardiac myosin bound to actin-tropomyosin.,Helical reconstruction of the human cardiac actin-tropomyosin-myosin complex in complex with ADP-Mg2+,MOTOR PROTEIN,ACTC1,,"GO:0005884, GO:0044297, GO:0005737, GO:0005869, GO:0030175, GO:0030027, GO:0030017, GO:0017022, GO:0007015, GO:0033275, GO:0060047, GO:0090131, GO:0010628, IPR004000, IPR020902, IPR004001, IPR043129",2,8EFH,Wildtype,B6VNT8,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8EG0,,,,,,8EG0,Structures and mechanisms of tRNA methylation by METTL1-WDR4.,CryoEM structure of human METTL1-WDR4 in complex with Lys-tRNA and SAH,TRANSFERASE/RNA,WDR4,,"GO:0005694, GO:0005829, GO:0005654, GO:0005634, GO:0043527, GO:0006974, GO:0106004, GO:0006400, IPR028884, IPR015943, IPR001680, IPR036322, P57081",1,8EG0,Wildtype,P57081,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,4
8F1G,,,,,,8F1G,Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.,Crystal structure of human WDR5 in complex with compound WM662,ONCOPROTEIN,"WDR5, BIG3",,"GO:0140672, GO:0000123, GO:0035097, GO:0072686, GO:0071339, GO:0044665, GO:0044666, GO:0044545, GO:0005654, GO:0005634, GO:0048188, GO:0042393, GO:0035064, GO:0006325, GO:0006094, GO:0043966, GO:0044154, GO:0051568, GO:0043984, GO:0043981, GO:0043982, GO:0051572, GO:0031175, GO:0045722, GO:0051571, GO:0045893, GO:0051726, GO:0051302, GO:1900095, GO:0045995, GO:0031063, GO:0006357, GO:0006355, GO:0090043, GO:0001501, IPR020472, IPR015943, IPR001680, IPR019775, IPR036322, P61964",1,8F1G,Wildtype,P61964,UniProt,C19 H18 Cl N5 O4,415.83,X8N,"(2S)-2-({(2S)-3-(3'-chloro[1,1'-biphenyl]-4-yl)-1-oxo-1-[(1H-tetrazol-5-yl)amino]propan-2-yl}oxy)propanoic acid",CC(C(=O)O)OC(Cc1ccc(cc1)c2cccc(c2)Cl)C(=O)Nc3[nH]nnn3,2
8F9Z,,,,,,8F9Z,Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.,"Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-14204, an HIV-1 gp120 antagonist",VIRAL PROTEIN/INHIBITOR,HIV-1 Env,,"IPR036377, IPR000777",1,8F9Z,Wildtype,A0A0M3KKW8,UniProt,C17 H16 F3 N5 O2 S,411.401,XKW,"(5M)-N-{(1S)-2-amino-1-[5-(hydroxymethyl)-1,3-thiazol-2-yl]ethyl}-5-[5-(trifluoromethyl)pyridin-2-yl]-1H-pyrrole-2-carboxamide",c1cc(ncc1C(F)(F)F)c2ccc([nH]2)C(=O)NC(CN)c3ncc(s3)CO,3
8FA0,,,,,,8FA0,Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.,"Crystal structure of clade A/E 93TH057 HIV-1 gp120 core in complex with NBD-14208, an HIV-1 gp120 antagonist",VIRAL PROTEIN,HIV-1 Env,,"IPR036377, IPR000777",1,8FA0,mutant,A0A0M3KKW8,UniProt,C18 H17 Cl F2 N4 O3 S,442.867,XKR,"N-{(1S)-2-amino-1-[4,5-bis(hydroxymethyl)-1,3-thiazol-2-yl]ethyl}-5-(4-chloro-3,5-difluorophenyl)-1H-pyrrole-2-carboxamide",c1cc([nH]c1c2cc(c(c(c2)F)Cl)F)C(=O)NC(CN)c3nc(c(s3)CO)CO,3
8GXB,,,,,,8GXB,Structure-based investigations of the NAD+-II riboswitch.,Crystal structure of NAD+ -II riboswitch in complex with NAD+,PROTEIN/RNA,SNRPA,,"GO:0005654, GO:0005634, GO:0005681, GO:0005685, GO:0046540, GO:0042802, GO:0003723, GO:0030619, GO:1990446, GO:0000398, IPR012677, IPR035979, IPR000504, IPR034407, IPR034409, P09012",2,8GXB,mutant,P09012,UniProt,C21 H27 N7 O14 P2,663.425,NAD,NICOTINAMIDE-ADENINE-DINUCLEOTIDE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)O)O)O)O)C(=O)N,3
8GXC,,,,,,8GXC,Structure-based investigations of the NAD+-II riboswitch.,Crystal structure of NAD+ -II riboswitch in complex with NMN,PROTEIN/RNA,SNRPA,,"GO:0005654, GO:0005634, GO:0005681, GO:0005685, GO:0046540, GO:0042802, GO:0003723, GO:0030619, GO:1990446, GO:0000398, IPR012677, IPR035979, IPR000504, IPR034407, IPR034409, P09012",1,8GXC,mutant,P09012,UniProt,C11 H16 N2 O8 P,335.227,NMN,BETA-NICOTINAMIDE RIBOSE MONOPHOSPHATE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)(O)O)O)O)C(=O)N,3
8H78,,,,,,8H78,"Discovery of TP0597850: A Selective, Chemically Stable, and Slow Tight-Binding Matrix Metalloproteinase-2 Inhibitor with a Phenylbenzamide-Pentapeptide Hybrid Scaffold.",Crystal structure of human MMP-2 catalytic domain in complex with inhibitor,HYDROLASE,MMP2,3.4.24.24,,1,8H78,Wildtype,,,C41 H57 N9 O13 S,916.009,L2U,"(2~{R})-2-[[4-[(4-aminocarbonylphenyl)carbonylamino]phenyl]sulfonylamino]-5-[(2~{S},4~{S})-4-azanyl-2-[[(2~{S})-1-[[(2~{S})-1-[(5-azanyl-5-oxidanylidene-pentyl)amino]-5-oxidanyl-1,5-bis(oxidanylidene)pentan-2-yl]-methyl-amino]-4-methyl-1-oxidanylidene-pentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxidanylidene-pentanoic acid",CC(C)CC(C(=O)N(C)C(CCC(=O)O)C(=O)NCCCCC(=O)N)NC(=O)C1CC(CN1C(=O)CCC(C(=O)O)NS(=O)(=O)c2ccc(cc2)NC(=O)c3ccc(cc3)C(=O)N)N,5
8HC2,,,,,,8HC2,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 1 YB9-258 Fab (1 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HC2,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HC3,,,,,,8HC3,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 2 YB9-258 Fabs (2 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HC3,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HC4,,,,,,8HC4,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 wildtype spike trimer (6P) in complex with 3 YB9-258 Fabs and 3 R1-32 Fabs (3 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HC4,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
8HC5,,,,,,8HC5,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 wildtype S1 in complex with YB9-258 Fab and R1-32 Fab,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HC5,Wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8HC6,,,,,,8HC6,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,"SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB9-258 Fab, focused refinement of Fab region",VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HC6,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HC7,,,,,,8HC7,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,"SARS-CoV-2 Omicron BA.1 spike trimer (6P) complex with YB9-258 Fab, focused refinement of RBD-dimer region",VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HC7,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HC8,,,,,,8HC8,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,"SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB13-292 Fab, focused refinement of Fab region",VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HC8,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8HC9,,,,,,8HC9,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (3 RBD down),VIRAL PROTEIN/IMMUNE SYSTEM,,"S, 2","GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HC9,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HCA,,,,,,8HCA,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (1 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HCA,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HCB,,,,,,8HCB,Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.,SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (2 RBD up),VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8HCB,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
8HU6,,,,,,8HU6,"The discovery of 3,3-dimethyl-1,2,3,4-tetrahydroquinoxaline-1-carboxamides as AMPD2 inhibitors with a novel mechanism of action.",AMP deaminase 2 in complex with AMP,HYDROLASE,AMPD2,3.5.4.6,"GO:0005829, GO:0003876, GO:0042802, GO:0046872, GO:0046033, GO:0052652, GO:0097009, GO:0006188, GO:0032264, IPR006650, IPR006329, IPR029749, IPR032466, Q01433",1,8HU6,Wildtype,Q01433,UniProt,C10 H14 N5 O7 P,347.221,AMP,ADENOSINE MONOPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)O)O)O)N,4
8HUB,,,,,,8HUB,"The discovery of 3,3-dimethyl-1,2,3,4-tetrahydroquinoxaline-1-carboxamides as AMPD2 inhibitors with a novel mechanism of action.",AMP deaminase 2 in complex with an inhibitor,HYDROLASE,AMPD2,3.5.4.6,"GO:0005829, GO:0003876, GO:0042802, GO:0046872, GO:0046033, GO:0052652, GO:0097009, GO:0006188, GO:0032264, IPR006650, IPR006329, IPR029749, IPR032466, Q01433",1,8HUB,Wildtype,Q01433,UniProt,C18 H21 N3 O,295.379,N4X,"3,3-dimethyl-4-(phenylmethyl)-2~{H}-quinoxaline-1-carboxamide",CC1(CN(c2ccccc2N1Cc3ccccc3)C(=O)N)C,3
